(Lung[TA])
3,062 results
  • Dupilumab Alleviates Pulmonary Fibrosis by Interrupting Profibrotic Macrophage-Fibroblast Crosstalk and IL4R/JAK/STAT Signaling. [Journal Article]
    Lung. 2026 Sep 16; 204(1).Chen Q, Zhang Y, … Huang HLUNG
  • CONCLUSIONS: Dupilumab attenuates pulmonary fibrosis by disrupting profibrotic macrophage-fibroblast crosstalk and suppressing fibroblast activation. In preclinical models, dupilumab mitigated BLM-induced pulmonary inflammation and early-stage fibrosis in mice and inhibited the TGF-β1-Smad and JAK-STAT signal transduction cascades. These findings identify IL-4Rα-mediated signaling as a promising intervention point in pulmonary fibrosis and support further investigation of dupilumab as a candidate therapy for fibrotic lung diseases.
  • Inhalable Dry Powders of Antimicrobial Agents in Respiratory Diseases. [Review]
    Lung. 2026 Sep 16; 204(1).Shafi H, Encinas-Basurto D, … Mansour HMLUNG
  • CONCLUSIONS: Antimicrobial DPIs are evolving toward precision pulmonary therapies, highlighting their expanding role in chronic infections, pandemic preparedness, and next-generation pulmonary anti-infective therapy. Overcoming dose, deposition, stability, andtranslational barriers will be critical for broader clinical adoption.